Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL29397040 | 1.00 | RAB9A (0.50) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL2073386 | 1.00 | RAB9A (0.50) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL2075174 | 1.00 | RAB9A (0.50) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL28329484 | 0.94 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL16516335 | 0.87 | SMN1; SMN2 (0.57) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL8901469 | 0.87 | SMN1; SMN2 (0.57) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL4774682 | 0.85 | KDM4E (0.56) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL16516333 | 0.84 | KDM4E (0.54) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL4631509 | 0.84 | SMN1; SMN2 (0.54) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 | |
| Benzimidazole SCHEMBL158526 | 0.84 | SMN1; SMN2 (0.54) | RAB9ASMN1; SMN2HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581217-A4 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1581217-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | claimed |
| EP-4731306-A1 | CYSTOBACTAMID DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025003147-A1 | CYSTOBACTAMID DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-01-02 | — | — | WO | disclosed |
| CN-117986511-A | Quaternary ammonium type covalent organic framework compound and preparation method of anion exchange membrane thereof | 大连理工大学 | 2024-05-07 | — | — | CN | disclosed |
| WO-2021162070-A1 | METHOD FOR PRODUCING MONOMER FOR NUCLEIC ACID PRODUCTION | 東レ株式会社 | 2021-08-19 | — | — | WO | disclosed |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2021-05-20 | — | — | US | disclosed |
| CN-109071579-B | Method for producing monomer for single-stranded nucleic acid molecule | 住友化学株式会社 | 2021-05-14 | — | — | CN | disclosed |
| EP-3450439-B1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | SUMITOMO CHEMICAL CO (JP) | 2021-01-20 | — | — | EP | disclosed |
| EP-3634972-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | Teva Czech Industries s.r.o. (CZ) | 2020-04-15 | — | — | EP | disclosed |
| US-20120202856-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-09 | — | — | US | disclosed |
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | disclosed |
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| WO-2010132247-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202856-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | RAB9A 2533/4885SMN1; SMN2 1255/4885HTT 4162/4885 |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | RAB9A 1985/4885SMN1; SMN2 4631/4885HTT 4541/4885 |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | UNG, SAMHD1, ALKBH1 | RAB9A 2077/4885SMN1; SMN2 960/4885HTT 2449/4885 |
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | RAB9A 2234/4885SMN1; SMN2 518/4885HTT 3454/4885 |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | RAB9A 2807/4885SMN1; SMN2 2716/4885HTT 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.